Research programme: cancer stem cell inhibitors - Chugai Pharmaceutical
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chugai Pharmaceutical
- Mechanism of Action Stem cell inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Cancer metastases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer-metastases(Prevention) in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Prevention of relapse) in Japan
- 19 Oct 2012 Early research in Cancer metastases (prevention) in Japan (unspecified route)